Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx, Inc.

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.75M -	504K 71.13%	1.33M 164.48%	9.05M 579.14%	2.62M 71.07%
accumulated other comprehensive income loss			-20K -	-221K 1,005.00%	547K 347.51%
cash and cash equivalents	34.58M -	46.60M 34.76%	104.62M 124.52%	64.18M 38.65%	394.58M 514.82%
cash and short term investments	34.58M -	46.60M 34.76%	104.62M 124.52%	254.84M 143.59%	702.02M 175.48%
common stock	1K -	1K 0%	1K 0%	44K 4,300%	52K 18.18%
deferred revenue					50.53M -
deferred revenue non current					170.67M -
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt				52.17M -	50.84M 2.55%
long term investments					27.17M -
net debt	-34.58M -	-46.60M 34.76%	-104.62M 124.52%	23.95M 122.89%	-296.96M 1,339.80%
net receivables
other assets					11.77M -
other current assets	621K -	1.21M 94.85%	2.05M 69.34%	12.03M 487.02%	14.35M 19.27%
other current liabilities	1.29M -	4.77M 268.68%	13.51M 183.45%	11.68M 13.57%	18.30M 56.71%
other liabilities
other non current assets	1.19M -	3.44M 189.07%	5.66M 64.53%	7.06M 24.92%	-97.00M 1,473.09%
other non current liabilities	73.29M -	116.14M 58.48%	235.45M 102.73%
othertotal stockholders equity	308K -	1.42M 361.36%	-20.28M 1,527.09%	523.92M 2,683.56%	874.26M 66.87%
preferred stock			28.89M -
property plant equipment net	4.33M -	4.90M 13.16%	10.32M 110.57%	39.89M 286.61%	69.83M 75.05%
retained earnings	-33.05M -	-65.14M 97.12%	-130.11M 99.73%	-318.79M 145.01%	-389.48M 22.17%
short term debt				35.96M -	46.78M 30.10%
short term investments			73.78M -	190.66M 158.40%	307.43M 61.25%
tax assets
tax payables
total assets	43.59M -	57.69M 32.36%	128.78M 123.22%	313.82M 143.68%	825.13M 162.93%
total current assets	38.07M -	49.36M 29.65%	112.81M 128.56%	266.86M 136.56%	716.36M 168.44%
total current liabilities	3.04M -	5.27M 73.45%	14.85M 181.64%	56.69M 281.90%	118.24M 108.56%
total debt				88.13M -	97.63M 10.77%
total investments			73.78M -	190.66M 158.40%	334.60M 75.50%
total liabilities	76.33M -	121.41M 59.07%	250.30M 106.15%	108.86M 56.51%	339.75M 212.09%
total liabilities and stockholders equity	43.59M -	57.69M 32.36%	128.78M 123.22%	313.82M 143.68%	825.13M 162.93%
total non current assets	5.52M -	8.34M 51.06%	15.97M 91.59%	46.95M 193.96%	97.00M 106.57%
total non current liabilities	73.29M -	116.14M 58.48%	235.45M 102.73%	52.17M 77.84%	221.51M 324.60%
total stockholders equity	-32.74M -	-63.72M 94.64%	-121.52M 90.70%	204.95M 268.67%	485.38M 136.82%

COM:ARCELLX

Arcellx, Inc.

Last Close

87.22

22/11 21:00

Market Cap

3.07B

Beta: -

Volume Today

342.91K

Avg: -

Preview